News & Events
< Back to News Overview
ChemGenex Investigators Present Data on Clinical Activity of Omacetaxine in Imatinib-Resistant Chronic Myeloid Leukemia Patients with the T315I Mutation at International Leukemia Conference
01 / 04 / 2008
ChemGenex Pharmaceuticals (ASX: CXS, NASDAQ: CXSP) has announced interim results from its ongoing phase 2/3 trial of omacetaxine mepesuccinate (formerly known as Ceflatoninr) in chronic myeloid leukemia (CML) patients with the T315I mutation. The data continue to show an increase in the number of patients responding, with increasing duration of response in chronic and accelerated phase patients.
Dr. David Marin of the Hammersmith Hospital, Imperial College London is delivering an oral presentation of the updated clinical data on behalf of a team of leading international hematologists at the New Directions in Leukemia Research (NDLR) conference being held at the Sunshine Coast, Queensland, Australia later today.
The registration-directed clinical trial of omacetaxine is in imatinib (Gleevecr)-resistant chronic myeloid leukemia (CML) patients with the T315I mutation. The mutation causes resistance to imatinib and second-generation tyrosine kinase inhibitors including dasatinib and nilotinib and is acknowledged as a major therapeutic challenge in the treatment of CML, and an unmet medical need. To date 34 patients have been enrolled in the study, and data will be presented from 25 evaluable patients: 15 in chronic phase, 4 in accelerated phase and 6 in blast phase. Highlights of the data include:
Hematologic and/or cytogenetic responses in 86% of chronic phase patients on trial.
Complete hematologic responses (CHR) in 60% of chronic phase patients, and cytogenetic responses in 20% of chronic phase patients.
Hematologic responses in all accelerated phase patients and in 2 of 6 blast phase patients.
Two chronic phase patients have maintained their complete hematologic responses for more than 14 months.
Median durations of hematologic response for chronic and accelerated phase patients of 8.5 months and 9.9 months, respectively.
Omacetaxine therapy is associated with myelosuppression which is manageable and reversible.
"This is a positive expansion on the clinical data presented by the ChemGenex team at ASH in 2007," said Dr. Marin. "We are seeing that omacetaxine has a beneficial effect on the majority of patients with the T315I mutation. These are patients who no longer respond to tyrosine kinase inhibitor therapy, and for whom a novel therapy is needed."
"We are very pleased with the updated preliminary clinical data on omacetaxine in T315I positive CML patients" said Dr. Greg Collier, ChemGenex's Managing Director and Chief Executive Officer. "We are seeing an increase in the number of patients who are responding to omacetaxine and a prolongation of response duration in chronic and accelerated phase patients. We look forward to the completion of clinical trial enrollment within the year, and to regulatory submission after that time."
Dr. David Marin of the Hammersmith Hospital, Imperial College London is delivering an oral presentation of the updated clinical data on behalf of a team of leading international hematologists at the New Directions in Leukemia Research (NDLR) conference being held at the Sunshine Coast, Queensland, Australia later today.
The registration-directed clinical trial of omacetaxine is in imatinib (Gleevecr)-resistant chronic myeloid leukemia (CML) patients with the T315I mutation. The mutation causes resistance to imatinib and second-generation tyrosine kinase inhibitors including dasatinib and nilotinib and is acknowledged as a major therapeutic challenge in the treatment of CML, and an unmet medical need. To date 34 patients have been enrolled in the study, and data will be presented from 25 evaluable patients: 15 in chronic phase, 4 in accelerated phase and 6 in blast phase. Highlights of the data include:
Hematologic and/or cytogenetic responses in 86% of chronic phase patients on trial.
Complete hematologic responses (CHR) in 60% of chronic phase patients, and cytogenetic responses in 20% of chronic phase patients.
Hematologic responses in all accelerated phase patients and in 2 of 6 blast phase patients.
Two chronic phase patients have maintained their complete hematologic responses for more than 14 months.
Median durations of hematologic response for chronic and accelerated phase patients of 8.5 months and 9.9 months, respectively.
Omacetaxine therapy is associated with myelosuppression which is manageable and reversible.
"This is a positive expansion on the clinical data presented by the ChemGenex team at ASH in 2007," said Dr. Marin. "We are seeing that omacetaxine has a beneficial effect on the majority of patients with the T315I mutation. These are patients who no longer respond to tyrosine kinase inhibitor therapy, and for whom a novel therapy is needed."
"We are very pleased with the updated preliminary clinical data on omacetaxine in T315I positive CML patients" said Dr. Greg Collier, ChemGenex's Managing Director and Chief Executive Officer. "We are seeing an increase in the number of patients who are responding to omacetaxine and a prolongation of response duration in chronic and accelerated phase patients. We look forward to the completion of clinical trial enrollment within the year, and to regulatory submission after that time."